Atomoxetine
Based on 4 publication(s) in Google Scholar
Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na+ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research.
For research use only. We do not sell to patients.
- Purity: 98.50%
- CAS No.: 83015-26-3
- Formula: C17H21NO
- Molecular Weight:255.35
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neuroprotective Compound Library
HY-L070
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Antidepressant Compound Library
HY-L108
-
Sodium Channel Blocker Library
HY-L118
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Atomoxetine
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
>5000 nM
Compound: 6 (Atomoxetine)
|
Inhibitory activity against Opioid receptor like 1 expressed in HEK293 cells
Inhibitory activity against Opioid receptor like 1 expressed in HEK293 cells
|
[PMID: 15225731] |
| HEK293 | IC50 |
4186 nM
Compound: 6 (Atomoxetine)
|
Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells
Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells
|
[PMID: 15225731] |
| HEK293 | IC50 |
4383 nM
Compound: 6 (Atomoxetine)
|
Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells
Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells
|
[PMID: 15225731] |
| HEK293 | IC50 |
>5000 nM
Compound: 6 (Atomoxetine)
|
Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells
Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells
|
[PMID: 15225731] |
| HEK293 | IC50 |
180 nM
Compound: 1
|
Inhibition of serotonin uptake at human SERT in human HEK293 cells
Inhibition of serotonin uptake at human SERT in human HEK293 cells
|
[PMID: 18550369] |
| HEK293 | IC50 |
5 nM
Compound: 1
|
Inhibition of norepinephrine uptake at human NET in human HEK293 cells
Inhibition of norepinephrine uptake at human NET in human HEK293 cells
|
[PMID: 18550369] |
| HEK293 | IC50 |
3 μM
Compound: 1
|
Inhibition of dopamine uptake at human DAT in human HEK293 cells
Inhibition of dopamine uptake at human DAT in human HEK293 cells
|
[PMID: 18550369] |
| HEK293 | IC50 |
180 nM
Compound: 1
|
Inhibition of serotonin uptake at human SERT expressed in HEK cells
Inhibition of serotonin uptake at human SERT expressed in HEK cells
|
[PMID: 18667309] |
| HEK293 | IC50 |
5 nM
Compound: 1
|
Inhibition of norepinephrine uptake at human NET expressed in HEK cells
Inhibition of norepinephrine uptake at human NET expressed in HEK cells
|
[PMID: 18667309] |
| HEK293 | IC50 |
3 μM
Compound: 1
|
Inhibition of dopamine uptake at human DAT expressed in HEK cells
Inhibition of dopamine uptake at human DAT expressed in HEK cells
|
[PMID: 18667309] |
| HEK293 | IC50 |
180 nM
Compound: atomoxetine
|
Inhibition of serotonin uptake at human SERT expressed in HEK293 cells
Inhibition of serotonin uptake at human SERT expressed in HEK293 cells
|
[PMID: 18672364] |
| HEK293 | IC50 |
5 nM
Compound: atomoxetine
|
Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells
Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells
|
[PMID: 18672364] |
| HEK293 | IC50 |
3 μM
Compound: atomoxetine
|
Inhibition of dopamine uptake at human DAT expressed in HEK293 cells
Inhibition of dopamine uptake at human DAT expressed in HEK293 cells
|
[PMID: 18672364] |
| HEK293 | IC50 |
190 nM
Compound: 6
|
Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter
Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter
|
[PMID: 18954038] |
| HEK293 | IC50 |
2.1 μM
Compound: 6
|
Inhibition of human ERG expressed in HEK293 cells by patch-clamp method
Inhibition of human ERG expressed in HEK293 cells by patch-clamp method
|
[PMID: 18954038] |
| HEK293 | IC50 |
3100 nM
Compound: 6
|
Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter
Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter
|
[PMID: 18954038] |
| HEK293 | IC50 |
5.1 nM
Compound: 6
|
Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter
Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter
|
[PMID: 18954038] |
| HEK293 | IC50 |
180 nM
Compound: atomoxetine
|
Inhibition of serotonin uptake at human SERT transfected in HEK cells
Inhibition of serotonin uptake at human SERT transfected in HEK cells
|
[PMID: 18954981] |
| HEK293 | IC50 |
5 nM
Compound: atomoxetine
|
Inhibition of norepinephrine uptake at human NET transfected in HEK cells
Inhibition of norepinephrine uptake at human NET transfected in HEK cells
|
[PMID: 18954981] |
| HEK293 | IC50 |
3 μM
Compound: atomoxetine
|
Inhibition of dopamine uptake at human DAT transfected in HEK cells
Inhibition of dopamine uptake at human DAT transfected in HEK cells
|
[PMID: 18954981] |
| HeLa | IC50 |
100 μM
Compound: Atomoxetine
|
Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay
Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay
|
[PMID: 25581017] |
| JAR | IC50 |
48 nM
Compound: 4
|
Inhibition of serotonin uptake at human SERT expressed in JAR cells
Inhibition of serotonin uptake at human SERT expressed in JAR cells
|
[PMID: 18771916] |
| JAR | IC50 |
48 nM
Compound: 5
|
Inhibition of serotonin uptake at human SERT expressed in JAR cells
Inhibition of serotonin uptake at human SERT expressed in JAR cells
|
[PMID: 18951020] |
| JAR | IC50 |
48 nM
Compound: 2
|
Inhibition of serotonin uptake at human SERT expressed in human JAR cells
Inhibition of serotonin uptake at human SERT expressed in human JAR cells
|
[PMID: 19329313] |
| MDCK | IC50 |
3 nM
Compound: 4
|
Inhibition of norepinephrine uptake at human NET expressed in MDCK cells
Inhibition of norepinephrine uptake at human NET expressed in MDCK cells
|
[PMID: 18771916] |
Atomoxetine (Tomoxetine) (1-100 μM; 0.5-20 seconds; tsA201 cells) interacts with the human heart muscle sodium channel (hNav1.5) in a state and dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats[1]
-
Dosage:0.3, 1 and 3 mg/kg
-
Administration:Intraperitoneal injection; for 4 hours
-
Result:Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold.
-
Animal Model:Spontaneously hypertensive rat (SHR)[3]
-
Dosage:0.1, 0.3, 1.25 and 5.0 mg/kg
-
Administration:Intraperitoneal injection and oral administration; for 14 days
-
Result:Had non-impact on the measurement of motor activity.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 83015-26-3
-
Appearance Oil
-
Molecular Weight 255.35
-
Formula C17H21NO
-
Color Colorless to light yellow
-
SMILES
CC(C=CC=C1)=C1O[C@@H](C2=CC=CC=C2)CCNC
-
Synonyms
Tomoxetine; (R)-Tomoxetine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Brain Behav Immun
Ghrelin modulates dopaminergic neuron formation and attention deficit hyperactivity disorder-like behaviors: From animals to human models. [Abstract]2021 May:94:327-337. PMID: 33412253 -
Ecotoxicol Environ Saf
Long-life triclosan exposure induces ADHD-like behavior in rats via prefrontal cortex dopaminergic deficiency. [Abstract]2024 Jul 23:282:116766. PMID: 39047361 -
Behav Brain Res
Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. [Abstract]2022 Feb 10:418:113642. PMID: 34755639 -
Solvent & Solubility
DMSO : 100 mg/mL (391.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (297 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. [Content Brief]
[2]. Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489. [Content Brief]
[3]. Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9162 mL | 19.5810 mL | 39.1619 mL | 97.9048 mL |
| 5 mM | 0.7832 mL | 3.9162 mL | 7.8324 mL | 19.5810 mL | |
| 10 mM | 0.3916 mL | 1.9581 mL | 3.9162 mL | 9.7905 mL | |
| 15 mM | 0.2611 mL | 1.3054 mL | 2.6108 mL | 6.5270 mL | |
| 20 mM | 0.1958 mL | 0.9790 mL | 1.9581 mL | 4.8952 mL | |
| 25 mM | 0.1566 mL | 0.7832 mL | 1.5665 mL | 3.9162 mL | |
| 30 mM | 0.1305 mL | 0.6527 mL | 1.3054 mL | 3.2635 mL | |
| 40 mM | 0.0979 mL | 0.4895 mL | 0.9790 mL | 2.4476 mL | |
| 50 mM | 0.0783 mL | 0.3916 mL | 0.7832 mL | 1.9581 mL | |
| 60 mM | 0.0653 mL | 0.3263 mL | 0.6527 mL | 1.6317 mL | |
| 80 mM | 0.0490 mL | 0.2448 mL | 0.4895 mL | 1.2238 mL | |
| 100 mM | 0.0392 mL | 0.1958 mL | 0.3916 mL | 0.9790 mL |
Powered by Bioz